Anthropic’s AI biolab finds ‘CRISPR-like’ DNA in viruses. What’s next?
Anthropic automated agents discovered a genomic system integrating reverse transcriptase to DNA inside viral data during work at the company's AI-assisted biology laboratory. These discoveries occur alongside existing drug research partnerships with six organizations, including Bristol Myers Squibb, BigHat Biosciences, and Generate Biomedicines. Meanwhile, the corporation maintains plans for a public listing on the Nasdaq under the ticker symbol ANT following an initial public offering registration filed on October 26, 2026. Rival technology firms are simultaneously applying biological artificial intelligence, with Radical Numerics advancing human trials using AI-engineered bacteriophages against antibiotic-resistant infections.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Anthropic agents discovered a system combining a reverse transcriptase to DNA within genomic data during research at the company's AI-assisted biology lab.
- ✓ Anthropic has drug research partnerships with six organizations, including BigHat Biosciences, Generate Biomedicines, and Bristol Myers Squibb.
- ✓ Anthropic filed an IPO registration on October 26, 2026, pursuing a public listing on the Nasdaq under the ticker ANT.
- ✓ Radical Numerics has begun human trials using AI-designed bacteriophages to treat antibiotic-resistant infections.
What changed
Anthropic agents identified a genetic system combining a reverse transcriptase to DNA within viral genomic data.
Live updates
-
Anthropic AI Lab Detects CRISPR-Like DNA Systems in Viral Genomes
Anthropic automated agents discovered a genomic system integrating reverse transcriptase to DNA inside viral data during work at the company's AI-assisted biology laboratory. These discoveries occur alongside existing drug research partnerships with six organizations, including Bristol Myers Squibb, BigHat Biosciences, and Generate Biomedicines. Meanwhile, the corporation maintains plans for a public listing on the Nasdaq under the ticker symbol ANT following an initial public offering registration filed on October 26, 2026. Rival technology firms are simultaneously applying biological artificial intelligence, with Radical Numerics advancing human trials using AI-engineered bacteriophages against antibiotic-resistant infections.
Why it matters
The convergence of artificial intelligence and genetic research accelerates novel biological discoveries and commercial applications. Anthropic balances its genomic investigations with active drug research collaborations and preparations for a public stock offering. Other market participants are actively translating digital biological designs into clinical treatments for stubborn bacterial infections.
What is confirmed
- Anthropic agents discovered a system combining a reverse transcriptase to DNA within genomic data during research at the company's AI-assisted biology lab.
- Anthropic has drug research partnerships with six organizations, including BigHat Biosciences, Generate Biomedicines, and Bristol Myers Squibb.
- Anthropic filed an IPO registration on October 26, 2026, pursuing a public listing on the Nasdaq under the ticker ANT.
- Radical Numerics has begun human trials using AI-designed bacteriophages to treat antibiotic-resistant infections.
What to watch next
- Progression of the Anthropic IPO under ticker ANT on the Nasdaq
- Updates on Anthropic drug research partnerships with Bristol Myers Squibb, BigHat Biosciences, and Generate Biomedicines
- Results from Radical Numerics human trials using AI-designed bacteriophages
confidence 100%Sources used for this update (2)
- www.zacks.com — Anthropic IPO 2026 Guide: Price Predictions, Dates, and Everything You Need to Know
- claude.com — Claude Platform | Claude by Anthropic
-
Anthropic AI Biolab identifies CRISPR-like DNA in viruses
Anthropic agents discovered a system combining a reverse transcriptase to DNA within genomic data during research at the company's AI-assisted biology lab. These findings coincide with Anthropic's drug research partnerships with six organizations, including BigHat Biosciences, Generate Biomedicines, and Bristol Myers Squibb. The company is currently pursuing a public listing on the Nasdaq under the ticker ANT, following an IPO registration filed on October 26, 2026. While Anthropic explores biological data, other AI firms like Radical Numerics have begun human trials using AI-designed bacteriophages to treat antibiotic-resistant infections.
Why it matters
The intersection of AI and molecular biology allows for the rapid identification of genetic systems and the design of synthetic viruses. This trend is moving toward clinical applications, as seen with FDA-authorized compassionate use trials for AI-generated phages. These developments occur as AI companies seek to prove real-world value and ROI through deep technical integration.
What is confirmed
- Anthropic filed an initial public offering registration with the U.S. Securities and Exchange Commission on October 26, 2026.
- Anthropic agents identified a system combining a reverse transcriptase to DNA within genomic data.
- Anthropic is collaborating on drug research with six organizations, including Generate Biomedicines, BigHat Biosciences, and Bristol Myers Squibb.
Still unconfirmed
- The FDA authorized a trial for AI-designed bacteriophages from Radical Numerics' Omnii-1 model for use in a human patient.
- Researchers at Aarhus University found that bacteriophages inside dead bacteria allow them to generate DNA.
What to watch next
- Results from the Radical Numerics human trial for antibiotic-resistant infections
- The official pricing and launch date of the Anthropic IPO on the Nasdaq
confidence 90%Sources used for this update (3)
- economictimes.indiatimes.com — uttama thilavali guide cloud process database hantavanthavagi ...
- economictimes.indiatimes.com — molecular biology: Latest News & Videos, Photos about ...
- www.healthandme.com — AI-Created Virus Injected Into A Human For The First Time To ...
-
Anthropic AI Agents Identify CRISPR-like System in Virus DNA
Anthropic agents identified a system combining a reverse transcriptase to DNA within genomic data, according to company presentations from September 23, 2026. The findings emerged from an AI-assisted biology lab utilizing Claude agents. Alongside these biological research milestones, Anthropic outlined drug research collaborations with six organizations, including Bristol Myers Squibb, Generate Biomedicines, and BigHat Biosciences. The company also filed an initial public offering registration on October 26, 2026, with the U.S. Securities and Exchange Commission under the proposed Nasdaq ticker ANT.
Why it matters
The integration of frontier artificial intelligence into life sciences highlights a push toward automated laboratory discovery. While partnerships with pharmaceutical developers point to commercial applications, regulatory filings temper immediate expectations for rapid scientific breakthroughs. The identification of novel genomic systems raises both research possibilities and technical questions regarding automated biological analysis.
What is confirmed
- Anthropic presented initial findings from its AI-assisted biology lab on September 23, 2026.
- Claude agents identified a system combining a reverse transcriptase to DNA in genomic data.
- Anthropic outlined collaborations with six organizations, including Bristol Myers Squibb, Generate Biomedicines, and BigHat Biosciences.
- Anthropic filed a Form S-1 initial public offering registration with the U.S. Securities and Exchange Commission on October 26, 2026, under the proposed Nasdaq ticker ANT.
Still unconfirmed
- The discovery by Claude agents represents a definitive milestone for AI-driven scientific discovery.
What to watch next
- Further technical validation and functional confirmation of the discovered enzyme system.
- Market performance and progression of Anthropic's initial public offering under ticker ANT.
confidence 100%Sources used for this update (6)
- best-ai.news — Anthropic — AI News Today
- finance.yahoo.com — Anthropic Announced New Achievements in Drug Research and Lab ...
- aivancity.ai — With Claude, a new milestone for biological research?
- crvscience.com — Anthropic’s IPO Filing Spotlights Life Sciences AI: From Wet ...
- dev.to — Anthropic's Claude Agents Discover CRISPR-like Enzyme System ...
- aivancity.ai — Avec Claude, une nouvelle étape pour la recherche en biologie ?
-
Anthropic AI Finds Virus DNA Pattern, Sparking Debate
Anthropic deployed approximately 950 Claude agents on a DNA database for 21 hours, allowing an agent to spot a repeat pattern in a virus's DNA. While press releases tout major scientific breakthroughs, the company's IPO filing tempers expectations on how quickly AI leads to big discoveries. Gene editing experts state the finding is not a gene editing tool like CRISPR, and makers cannot yet confirm its function. The discovery opens new possibilities in genetic research alongside bioethical questions regarding the limits of AI in science.
Why it matters
Anthropic previously confirmed that a Bay Area biology lab is testing robots directed by its Claude AI following the identification of a novel CRISPR-like enzyme system in bacteriophages. That initial disclosure noted that ten reruns failed to find the pattern again, creating disputes over research priority and whether AI can outpace human scientists. The current reports highlight a tension between marketing claims of rapid breakthroughs and cautious IPO filings about the actual speed of AI-driven discovery.
What is confirmed
- Anthropic deployed approximately 950 Claude agents on a DNA database for 21 hours.
- An AI model identified a repeat pattern in virus DNA that resembles CRISPR.
- Gene editing experts state that the AI-spotted pattern is not a gene editing tool like CRISPR.
- Anthropic's IPO filing tempers expectations regarding the speed at which AI will lead to major scientific discoveries.
Still unconfirmed
- Makers and researchers cannot yet say what the newly found enzyme system actually does.
What to watch next
- Experimental validation of the biological function of the enzyme system.
- Resolution of the reproducibility dispute after ten reruns failed to recover the pattern.
confidence 95%Sources used for this update (4)
- www.wired.com — Anthropic Says It Will Revolutionize Biology—Some Day
- www.indiatoday.in — Did AI just find the next CRISPR? Why gene editing experts ...
- www.youtube.com — Claude Read Raw DNA and Found Something New - YouTube
- bioethicsobservatory.org — A new CRISPR discovered by AI? - bioethicsobservatory.org
-
Anthropic AI DNA Discovery Sparks Scientific Debate
Anthropic confirms a Bay Area biology lab is testing robots directed by its Claude AI. This follows a disclosure that the AI agent identified a novel CRISPR-like enzyme system called Array-associated Reverse Transcriptases in bacteriophages after analyzing reverse-transcriptase samples. While the company states the system independently took the first steps of a biological discovery, scientists remain unsure about the sequence, validation, and biological function. Ten reruns reportedly failed to find the pattern again, intensifying disputes over research priority and whether AI models can truly outpace human scientists.
Why it matters
The integration of artificial intelligence into biological research raises urgent questions about the pace of scientific discovery and research priority. As large language models begin guiding laboratory robots, the academic community faces intense pressure over whether computational tools are scooping human researchers. This capability bridges digital agents with physical laboratory automation, though fundamental validation of AI-generated biological findings remains a critical hurdle.
What is confirmed
- Anthropic confirms a Bay Area biology lab is testing Claude-directed robots with humans still in the loop.
- Anthropic announced that its AI agent Claude identified a novel CRISPR-like enzyme system called Array-associated Reverse Transcriptases in bacteriophages.
- Scientific American reports that Claude identified a DNA pattern resembling CRISPR, but sequence, validation, and biological function remain unclear.
Still unconfirmed
- Ten reruns of the experiment could not find the CRISPR-like pattern again.
What to watch next
- Formal peer-reviewed publication of the Array-associated Reverse Transcriptases discovery and biological validation data.
- Further independent replication attempts by academic laboratories to verify Claude's DNA pattern findings.
confidence 90%Sources used for this update (4)
- shattered.io — Anthropic Biology Lab: Claude Guides Lab Robots [2026]
- dev.to — Claude Found a CRISPR-Like Pattern in DNA. Ten Reruns Couldn ...
- www.nature.com — CRISPR-Cas9 genome editing - Latest research and news | Nature
- adiust.com — Why Anthropic’s Scientists Are Unsure About Claude’s DNA ...
-
Anthropic AI identifies ART enzyme system in biological data
Anthropic announced on September 23 that its AI agent Claude identified a novel CRISPR-like enzyme system called Array-associated Reverse Transcriptases (ART). The system analyzed roughly 200,000 reverse-transcriptase samples over 21 hours to find the DNA-repeat system in bacteriophages. Anthropic claims the AI independently took the first steps of a biological discovery. This event has intensified disputes over research priority and whether AI companies are scooping academic work, as researchers worry that large language models may now outpace human scientists in making major breakthroughs.
Why it matters
CRISPR technology allows for precise gene editing, making the discovery of similar systems highly valuable for biotech. The speed of this discovery highlights a shift where AI agents can sift through massive biological datasets faster than traditional human teams. This creates tension regarding how scientific credit is assigned when AI identifies patterns first.
What is confirmed
- Anthropic announced the discovery of the ART enzyme system on September 23.
- Claude analyzed roughly 200,000 reverse-transcriptase samples over 21 hours to identify the system.
- The ART system is a CRISPR-like novel enzyme system found in bacteriophages.
Still unconfirmed
- AI companies are scooping human academic work.
What to watch next
- Peer review or experimental validation of the ART system by independent biologists.
- Changes to academic research rules regarding AI-led discoveries.
- Anthropic's initial public offering timeline.
confidence 90%Sources used for this update (6)
- www.explainx.ai — Anthropic and Claude: News, Guides and Timeline | explainx.ai
- dev.to — Claude may have found a new CRISPR-like gene editing system
- www.happyrock.cloud — When AI Answers First: The ART Priority Dispute and the ...
- www.scientificamerican.com — Scientific American
- www.thinkfacility.com — AI news today: the stories, and what the people involved said
- mediabias.news — Nature media bias and reliability — MediaBias News
-
Anthropic AI Finds CRISPR-Like DNA as Scientific Community Debates AI Scooping
Anthropic's artificial intelligence system deployed 950 agents over 21 hours to analyze DNA sequence databases, uncovering a novel DNA-repeat system called ART in bacteriophages that resembles CRISPR. While IBM highlights how these AI agents help researchers sift through biological data more rapidly, the discovery has triggered anxiety among human researchers. Scientists worry that increasingly capable large language models will beat them to major scientific discoveries, with accusations mounting that AI companies are scooping human academic work. Meanwhile, Anthropic prepares for an expected initial public offering amid wider industry safety concerns and the rollout of its Claude Mythos model series.
Why it matters
The discovery of the ART system using automated AI agents marks a significant shift in how biological data is analyzed, moving artificial intelligence beyond coding and mathematics into complex genetic research. However, the speed of these AI-driven breakthroughs has sparked tension between tech firms and academic researchers who fear being outperformed. This technological acceleration coincides with Anthropic's corporate expansion, including plans for a major initial public offering and the restricted release of advanced models like Claude Mythos due to dual-use safety risks.
What is confirmed
- Anthropic's AI system found a novel DNA-repeat system called ART in bacteriophages, which resembles CRISPR in structure.
- The discovery used 950 AI agents analyzing DNA sequence databases over 21 hours.
- Wall Street is preparing for Anthropic's expected initial public offering.
- Anthropic's CEO recently called for an industry-wide slowdown over growing safety concerns.
Still unconfirmed
- Scientists worry that increasingly capable large language models will beat them to discoveries and accuse companies of scooping their work.
- An AI agent wrote that it could spot the repeats in the DNA by eye.
What to watch next
- Successful reproduction of the AI workflow and the ART enzyme's function by independent researchers.
- Further developments regarding Anthropic's expected initial public offering and market valuation.
- Broader academic policy responses to artificial intelligence systems performing autonomous biological discoveries.
confidence 90%Sources used for this update (11)
- platform.claude.com — Anthropic - Claude Platform
- www.cnn.com — Anthropic expected to IPO despite market uncertainty, AI slowdown...
- en.wikipedia.org — Claude Mythos - Wikipedia
- www.nature.com — Will AI scoop your science? Some researchers see a gloomy future | Nature
- www.bioin.or.kr — 앤트로픽(Anthropic), AI 생물학 연구소 출범
- claude.com — Build live dashboards and animate explainers with Claude
- www.scientificamerican.com — Claude just found a CRISPR-like DNA pattern, but even Anthropic's scientists aren't sure what it does | S....
- www.theangryoptimist.org — AI discovers a CRISPR-like system that researchers had missed
- india-employmentnews.com — Did AI discover a new biological system? Why did a scientist ...
- aiweekly.co — Scientists accuse OpenAI and Anthropic of scooping their work
- www.nature.com — Genetic techniques - Latest research and news | Nature
-
Anthropic's AI discovers 'CRISPR-like' DNA in viruses
Anthropic's AI system found a novel DNA-repeat system called ART in bacteriophages, resembling CRISPR in structure. The discovery was made using 950 AI agents analyzing DNA sequence databases over 21 hours. The scientific community is now focused on reproducing the AI workflow and the enzyme's function. IBM notes that this experiment shows how AI agents can help scientists sift through biological data and surface discoveries faster.
Why it matters
This discovery advances AI-driven biological exploration and has sparked controversy over its implications. The CRISPR gene-editing tool has revolutionized genetics and has potential applications in medicine and agriculture. The ART system's function and gene-editing capabilities are currently unknown.
What is confirmed
- Anthropic's Claude AI discovered a novel DNA-repeat system called ART in bacteriophages.
- The discovery was made using 950 AI agents analyzing DNA sequence databases over 21 hours.
- The ART system resembles CRISPR in structure.
- The specific function and gene-editing capabilities of the ART system are currently unknown.
Still unconfirmed
- Anthropic's AI agents discovered an unusual pattern in viral DNA similar to what's seen in the gene-editing tool CRISPR Cas-9.
What to watch next
- Independent reproduction of the AI workflow and the enzyme's function
- Further research on the ART system's function and gene-editing capabilities
- Potential applications of the ART system in medicine and agriculture
confidence 90%Sources used for this update (10)
- preview-www.nature.com — News in 2026 | Nature
- www.nature.com — News - Nature
- www.ibm.com — What Anthropic’s AI biology experiment actually showed | IBM
- www.cnn.com — Did AI find a new gene-editing tool? Why Anthropic’s ‘autonomous discovery’ is sparking controversy
- uptimecheck.com — Website Uptime Monitoring & Status Pages | UptimeCheck
- app.uptimecheck.com — Lost password - UptimeCheck
- uptimecheck.com — Pingdom Alternative | UptimeCheck
- uptimecheck.com — Better Stack Alternative | UptimeCheck
- uptimecheck.com — UptimeRobot Alternative | UptimeCheck
- app.uptimecheck.com — Resend activation - UptimeCheck
-
Anthropic AI identifies ART enzyme system in bacteriophages
Anthropic released findings on September 23, 2026, announcing that its Claude AI discovered a novel DNA-repeat system called ART in bacteriophages. This system resembles CRISPR in structure, though its specific function and gene-editing capabilities are currently unknown. The discovery resulted from a workflow using 950 AI agents that analyzed DNA sequence databases over 21 hours. While the company claims this advances AI-driven biological exploration, the scientific community is now focused on whether the AI workflow and the enzyme's function can be independently reproduced.
Why it matters
Bacteriophages are viruses that infect bacteria. Identifying new enzyme systems in these viruses could lead to new tools for genetic engineering or medical treatments. Anthropic is a San Francisco-based AI safety company founded by former OpenAI members.
What is confirmed
- Anthropic released the findings regarding the CRISPR-like system on September 23, 2026.
- The discovered DNA-repeat system is named ART.
- ART was found in bacteriophages, which are viruses that infect bacteria.
- The ART system resembles CRISPR in structure.
- The specific function and gene-editing activity of ART remain unknown.
Still unconfirmed
- One expert stated that the public relations announcement was live while experiments remained in the queue.
- The discovery's significance depends on whether the AI workflow can be independently reproduced.
What to watch next
- Independent reproduction of the AI workflow
- Experimental results confirming the biological function of ART
confidence 90%Sources used for this update (14)
- www.anthropic.com — Home \\ Anthropic
- en.wikipedia.org — Anthropic - Wikipedia
- claude.com — Claude
- www.anthropic.com — Company \ Anthropic
- claude.com — The AI for Problem Solvers | Claude by Anthropic
- anthropic.skilljar.com — Anthropic Courses
- academy.claude.com — Claude Academy · Learn to work and build with Claude
- finance.yahoo.com — Anthropic’s 950 AI Agents Uncover CRISPR-Like Enzyme System ...
- www.wired.com — Anthropic Says It Discovered a Crispr-Like System. Now What?
- www.theneuron.ai — Claude Spotted a CRISPR-Like DNA Pattern. Can It Be ...
- www.thedailystar.net — Claude discovers new enzyme system in Anthropic’s biology lab
- www.neoteo.com — Claude Helped Identify a CRISPR-Like DNA Pattern | NeoTeo
-
Anthropic AI Lab Discovers CRISPR-Like DNA in Viruses
Anthropic launched a life sciences research group and disclosed that its Claude artificial intelligence model autonomously flagged a novel enzyme system with CRISPR-like repeats in the genomes of giant viruses. The detection effort enlisted roughly 950 AI agents, which spent more than 21 hours combing through DNA sequence databases. Scientists have not yet determined what the newfound viral sequences do, leaving it unclear whether the function matches microbial CRISPR systems. Meanwhile, the Anthropic CEO stated that artificial intelligence could cure most major diseases within the next decade.
Why it matters
Artificial intelligence models are increasingly applied to vast metagenomic databases to uncover unexplored genetic material that can seed tools for biotechnology and medicine. Anthropic combined this computational approach with a physical biology wet lab in San Francisco, where human scientists and AI agents work together. However, independent scientists are questioning whether the discovery is truly original or what practical applications will follow.
What is confirmed
- Anthropic announced that its Claude AI model discovered a novel enzyme system with CRISPR-like repeats in the genomes of several giant viruses.
- The detection effort enlisted roughly 950 AI agents that spent more than 21 hours combing through DNA sequence databases.
- Anthropic launched a life sciences research group where human scientists and AI agents work together to design and conduct experiments.
- Researchers have not yet determined what the newfound viral sequences do or whether their function is similar to microbial CRISPR systems.
Still unconfirmed
- The Anthropic CEO stated that artificial intelligence could cure most major diseases within the next decade.
What to watch next
- Experimental results determining the actual function of the newfound viral sequences.
- Independent verification from outside scientists regarding the originality of the enzyme discovery.
confidence 95%Sources used for this update (15)
- Fox Business — Anthropic CEO says AI could cure most major diseases within next decade
- anthropic.com — Claude discovers a novel enzyme system with CRISPR-like repeats
- The Verge — Anthropic’s biolab made a discovery it’s comparing to Crispr
- Nature — Anthropic’s AI biolab finds ‘CRISPR-like’ DNA in viruses. What’s next?
- The New York Times — In a New Anthropic Lab, A.I. Turns to Biology
- www.cnet.com — Did Anthropic Really Make a Big Biology Breakthrough? We Asked Scientists to Weigh In
- techcrunch.com — Anthropic says its biology lab has already found something big
- www.nature.com — Anthropic’s AI biolab finds ‘CRISPR-like’ DNA in viruses. What’s next? | Nature
- www.alphaxiv.org — Autonomous AI Agents Discover Reverse Transcriptases with Tandem Repeat Arrays | alphaXiv
- www.thepaper.cn — AI科学家独立发现“类CRISPR”新系统，整个过程仅用21小时
- pubmed.ncbi.nlm.nih.gov — Anthropic's AI biolab finds 'CRISPR-like' DNA in viruses ...
- www.stardrive.org — Anthropic’s AI biolab finds ‘CRISPR-like’ DNA in viruses ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community